SCHEMBL298341

SCHEMBL298341

Cn1cc(-c2cnc3[nH]cc(C(=O)c4cccc(NS(=O)(=O)c5cccc(C(F)(F)F)c5)c4)c3c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.51
KIT P10721 4/20 0.49
NTRK1 P04629 1/20 0.49
PAK1 Q13153 2/20 0.46
PIK3CA P42336 1/20 0.46
CSF1R P07333 4/20 0.45
EGFR P00533 1/20 0.44
FGFR1 P11362 1/20 0.44
KDR P35968 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.43
PDPK1 O15530 1/20 0.42
PIK3CB P42338 1/20 0.42
BRD4 O60885 1/20 0.42
RIPK1 Q13546 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297367 0.93 ALK (0.48) ALKKITNTRK1PAK1PIK3CA
SCHEMBL297385 0.91 CYP3A4 (0.51) ALKPAK1PIK3CAEGFRFGFR1
SCHEMBL297485 0.90 ALK (0.49) ALKKITNTRK1PAK1PIK3CA
SCHEMBL298196 0.89 PAK1 (0.44) ALKKITNTRK1PAK1PIK3CA
SCHEMBL3710491 0.88 PAK1 (0.57) ALKPAK1PIK3CAEGFRFGFR1
SCHEMBL298470 0.88 PIK3CA (0.50) ALKPAK1PIK3CAEGFRFGFR1
SCHEMBL298351 0.87 PIK3CA (0.49) ALKPAK1PIK3CAEGFRFGFR1
SCHEMBL299321 0.87 PAK1 (0.45) ALKKITPAK1PIK3CACSF1R
SCHEMBL298148 0.86 EGFR (0.57) ALKPAK1PIK3CAEGFRFGFR1
SCHEMBL297843 0.83 GAA (0.48) KITNTRK1ALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF ALK 679/4885KIT 1330/4885NTRK1 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.